Other · developed by Protalix
PRX-105 is an investigational drug studied in Organophosphate Exposure.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01093859 | Early Phase 1 | Organophosphate Exposure | Completed | PLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Organophosphate Exposure
Updated Oct 25, 2026. Something wrong or missing? Report it on the PLX page.
See PLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PLX catalysts and pipeline →